Nesiritide
As of the edition of 20 October 2026, Nesiritide is a protein: marketed, first approved in 2001 (US); acts on NPR1; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2001
- Kind
- Protein
- Brand name
- Natrecor
- First approved
- 10 August 2001 (US)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Scios
- Registered trials
- 43, 15 stopped early
- Disease areas
- Heart and blood vessels; Pregnancy and women's health; Urinary and reproductive; Lungs and airways; Inherited and neonatal; Nutrition and metabolism
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route B because of this drug.
Companies on route B for this drug
In the product1 company is on route B because of Nesiritide.
See the 1 company on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| NPR1 | Atrial natriuretic peptide receptor 1 | P16066 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 6 | 3 | 0 | 1 |
| Phase 1 | 1 | 0 | 0 | 1 |
| Phase 2 | 14 | 9 | 0 | 5 |
| Phase 3 | 12 | 9 | 0 | 2 |
| Phase 4 | 10 | 3 | 0 | 6 |
| All trials | 43 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Scios | Originator and Lead sponsor of trials | 2001 to now |